April 3 (Reuters) - Sangamo Therapeutics Inc SGMO.O:
SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM
SANGAMO THERAPEUTICS INC: SANGAMO TO RECEIVE AN $18 MILLION UPFRONT LICENSE FEE
SANGAMO THERAPEUTICS INC: ELIGIBLE TO EARN UP TO $1.4 BILLION IN ADDITIONAL LICENSED TARGET FEES AND MILESTONE PAYMENTS
SANGAMO: AGREEMENT GRANTS LILLY RIGHTS TO EMPLOY CO'S NOVEL PROPRIETARY CAPSID, STAC-BBB, FOR UP TO 5 POTENTIAL DISEASE TARGETS
Source text: ID:nBw1y4wTga
Further company coverage: SGMO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.